Advertisement

Search Results

Advertisement



Your search for all items matches 31627 pages

Showing 1 - 50


cns cancers

Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma

The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...

head and neck cancer
issues in oncology
immunotherapy

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer

Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...

integrative oncology

Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment

Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...

cns cancers
genomics/genetics

Clonal and Subclonal Pathogenic Alterations at Diagnosis in High-Risk Neuroblastoma

In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...

ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor

In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...

breast cancer

Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate

In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...

issues in oncology
solid tumors

Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality

Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...

breast cancer
issues in oncology

Breast Cancer Mortality Rates May Have Stopped Declining

Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...

issues in oncology
global cancer care
health-care policy

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...

prostate cancer

Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer

A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...

solid tumors
breast cancer
issues in oncology
cardio-oncology
supportive care
symptom management

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer

A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...

prostate cancer
issues in oncology
genomics/genetics

Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone

Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...

hepatobiliary cancer
immunotherapy

Outcomes After Complete Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma

In a retrospective study reported in JAMA Network Open, Lim et al found that complete response to immunotherapy as first-line treatment of advanced hepatocellular carcinoma was associated with good outcomes. Study Details The study involved analysis of 228 patients who received atezolizumab and...

lung cancer

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...

solid tumors
immunotherapy

Combination of Immunotherapies for Advanced HPV-Associated Cancers

In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...

hepatobiliary cancer
issues in oncology

Novel Biomarkers May Improve Diagnosis of Gallbladder Cancer

Plasma proteins may be capable of distinguishing gallbladder cancer from cholecystitis, which could reduce unnecessary procedures and improve treatment options in patients with suspected gallbladder cancer, according to a recent study published by Nouairia et al in JHEP Reports. Gallbladder cancer...

gynecologic cancers
gastroesophageal cancer
head and neck cancer
skin cancer
issues in oncology

Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer

A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...

hematologic malignancies
multiple myeloma

MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma

In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...

lung cancer

Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC

In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...

colorectal cancer
pancreatic cancer
gastrointestinal cancer

Overcoming Resistance to KRAS G12C Inhibitors in Pancreatic and Colorectal Cancers

A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...

colorectal cancer

MSTFCRC Updates Recommendations for Colonoscopy Preparation

Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...

cns cancers

Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas

Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...

skin cancer
lymphoma
issues in oncology

Is There a Link Between Tattoos and Increased Cancer Risk?

Skin cancers and lymphoma may be more prevalent among individuals with tattoos compared with those without tattoos, according to a recent study published by Clemmensen et al in BMC Public Health. Prior research has shown that tattoo ink does not just remain at the site of injection—instead, when...

lung cancer
supportive care

Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC

Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...

breast cancer
genomics/genetics

Clinical Characteristics of Breast Cancer in Young BRCA Carriers

In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...

Francis S. Collins, MD, PhD, Retires From the National Institutes of Health

Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...

colorectal cancer
issues in oncology

Novel Prediction Score May Estimate Risk of Early-Onset Colorectal Cancer, Precancerous Polyps

Researchers have developed and validated a novel prediction model that may be capable of estimating the risk of colorectal cancer and advanced precancerous polyps in patients younger than 45 years, according to a recent study published by Wehbe et al in Digestive Diseases and Sciences. Background...

breast cancer
issues in oncology

Chemotherapy, Endocrine Therapy May Have Different Long-Term Physical Health Effects in Breast Cancer Survivors

The receipt of chemotherapy or endocrine therapy without chemotherapy could be associated with different long-lasting physical health declines among breast cancer survivors compared with those without breast cancer, according to a recent study published in JAMA Network Open. Background Physical...

hematologic malignancies
multiple myeloma

Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...

lung cancer

Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

As reported in the Journal of Clinical Oncology by Gautschi et al, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of selpercatinib in patients with RET fusion–positive non–small cell lung cancer (NSCLC).  Study Details The primary analysis of the trial...

breast cancer

Palbociclib Plus Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative Metastatic Breast Cancer

In an overall survival analysis of a South Korean phase II trial (Young-PEARL) reported in The Lancet Oncology, Ahn et al found no benefit with palbociclib plus exemestane and leuprorelin vs capecitabine in premenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast...

issues in oncology

The Importance of Diversity in Clinical Research

The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...

leukemia
genomics/genetics

Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML

An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...

colorectal cancer
issues in oncology

Decoding Varying Risk of Colorectal Cancer Among Different Steatotic Liver Disease Subgroups

Investigators have found that the risk of colorectal cancer may vary among steatotic liver disease subgroups and could be higher in patients with alcoholic liver disease, according to a recent study published by Kimura et al in Clinical Gastroenterology and Hepatology. Background Lifestyle-related...

issues in oncology

Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?

It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...

skin cancer

7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases

As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases. Study Details In the open-label multicenter study, 63...

prostate cancer

Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer

Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase...

breast cancer
issues in oncology

Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction

Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...

gastrointestinal cancer
issues in oncology

Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk

Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background  Gastric cancer is the fourth...

gastrointestinal cancer

ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...

prostate cancer

Overall Survival and HRQOL with Addition of  [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...

breast cancer

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early HER2-Positive Breast Cancer

In an analysis from the ShortHER trial reported in JAMA Oncology, Dieci et al identified 10-year outcomes with 9 weeks or 1 year of adjuvant trastuzumab plus chemotherapy according to level of tumor-infiltrating lymphocytes (TILs) in patients with early HER2-positive breast cancer.   Study Details...

breast cancer

Top Picks From SABCS 2024

Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...

bladder cancer

Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...

solid tumors
issues in oncology

Participation in Early Trials May Provide Some Patients With Access to Cancer Drugs Later FDA Approved

Nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that eventually receive U.S. Food and Drug Administration (FDA) approval, according to a recent study published by Ouimet et al in the Journal of the National Cancer Institute. The findings may have...

prostate cancer
genomics/genetics

BRCA1 Gene Mutations May Not Be Key to Prostate Cancer

Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...

solid tumors
immunotherapy

Novel Antibody-Toxin Conjugate Evaluated in Early Study

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of antibody-drug...

solid tumors
supportive care
palliative care
issues in oncology

New Study Uncovers Low Uptake of Supportive Care at End of Life in Patients With Advanced Cancer

Investigators have found that nearly 50% of patients with advanced cancer may receive potentially aggressive treatment at the expense of supportive care, despite considerable efforts to improve the quality of end-of-life care in the United States, according to a recent study published by Kwon et al ...

colorectal cancer
survivorship
issues in oncology

Physical Activity May Help Colorectal Cancer Survivors Live as Long as Those in General Population

Physical activity may help colorectal cancer survivors achieve long-term survival rates comparable to those of individuals in the general population, according to a recent study published by Brown et al in Cancer. Background Patients with colorectal cancer often face higher rates of premature...

breast cancer

Evaluation of Surrogate Endpoints for Overall Survival in Neoadjuvant Randomized Trials in Early Breast Cancer

In a study reported in Journal of Clinical Oncology, Conforti et al found that invasive disease–free survival with sufficient follow-up may be the best surrogate for overall survival in neoadjuvant randomized trials in early breast cancer. Study Details The study involved 11 trials with 15...

Advertisement

Advertisement




Advertisement